Body Fluid Collection And Diagnostics Market To Reach $50.18 Billion By 2030

Body Fluid Collection And Diagnostics Market Growth & Trends

The global body fluid collection and diagnostics market size is expected to reach USD 50.18 billion by 2030, registering a CAGR of 6.6% from 2025 to 2030, as per the new report by Grand View Research, Inc. owing to the growing prevalence of non-communicable and communicable diseases globally coupled with growing demand for rapid diagnostic tests for early detection of diseases. In May 2022, TECHKON developed a new method and device which could analyze body fluids and determine medical parameters and instantly diagnose diseases.

Furthermore, body fluid testing is mostly adopted by clinicians to help assess substantial information in regard to patients’ medical conditions, such as infection, inflammatory diseases, malignancy, and hemorrhage. Body fluid analysis is manually performed with optical microscopy, which is a gold-standard approach for cell counting. However, new automated methods for analysis have been introduced which have enhanced precision, and turnaround time, and have reduced inter-operator variability. Automatic analyzers offer improved efficiency, standardization, and accuracy along with accurate, reliable, and rapid counting of WBCs (differential) and red blood cells (RBCs) in cerebrospinal and other body fluids.

The increasing demand for Direct-to-Consumer testing (DTC) is projected to boost the demand for body fluid collection and would enable easy sample collection by end users. Several players offer the DTC sample collection kits to consumers directly and thus analyze the collected samples. For instance, in April 2022, Labcorp launched an innovative healthcare service with Getlabs that aims to easily test consumers at their homes. People can schedule a home blood specimen collection when it’s suitable for them.

Key players operating in the body fluid collection and diagnostics market are considering several initiatives such as entering into a strategic alliance, new product launches, and regional expansion among others. For instance, in December 2022, Roche announced receiving U.S. FDA authorization for its Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. These assays would be used to measure biomarkers for Alzheimer’s disease. Similarly, in October 2022, C?N Diagnostics announced the success of the PrecivityAD Blood Test which can assist clinicians in Alzheimer’s disease diagnosis. 

 Request a free sample copy or view report summary: Body Fluid Collection And Diagnostics Market Report

Body Fluid Collection And Diagnostics Market Report Highlights

• The overall growth of the market is attributed to the growing adoption of at-home sample collection tests and the easy availability of diagnostic kits for customers

• By sample type, the blood segment dominated the market in 2024, owing to the introduction of advanced techniques such as short tandem repeat, single-nucleotide polymorphism analysis, and others

• By technology, the Polymerase Chain Reaction (PCR) segment dominated the market owing to the growing application of the technology for the detection of diseases. Moreover, the COVID-19 pandemic has also contributed to the market’s growth

• By application, the diagnostics and monitoring segment dominated the body fluid collection and diagnostics market in 2022 as it helps clinicians to identify changes to cellular networks and physiological conditions in diseased tissues

• By product, the kits and consumables segment captured the highest share in 2024, owing to increasing demand for rapid and cost-effective kits coupled with easing government regulations

• North America dominated the market in 2024 due to the presence of several market players in the region coupled with increasing product launches and strategic initiatives

Body Fluid Collection And Diagnostics Market Segmentation

Grand View Research has segmented the global body fluid collection and diagnostics market report on the basis of sample, technology, application, product, and region:

Body Fluid Collection And Diagnostics Sample Outlook (Revenue, USD Million, 2018 - 2030)

• Blood

• Saliva

• Urine

• Cerebrospinal Fluid

Body Fluid Collection And Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Tests/Services

• Kits & Consumables

• Instruments

Body Fluid Collection And Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Next Generation Sequencing

• Next Generation Sequencing (NGS)

• Polymerase Chain Reaction (PCR)

• Fluorescence in situ hybridization (FISH)

• Others

Body Fluid Collection And Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnostics & Monitoring

• Therapeutic Decision Making

• Prognostics & Screening

Body Fluid Collection And Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players in the Body Fluid Collection And Diagnostics Market

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories

• Illumina, Inc

• Guardant Health

• QIAGEN

• Johnson & Johnson

• Laboratory Corporation of America Holdings

• Biocept Inc

• F. Hoffmann-La Roche Ltd.

• MDxHealth SA.